Lingdolinurad - Atom Bioscience
Alternative Names: ABP-671Latest Information Update: 09 Dec 2024
At a glance
- Originator Atom Bioscience
- Class Antigouts; Antirheumatics; Small molecules; Uricosurics
- Mechanism of Action SLC22A12 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Gout
- Phase II Hyperuricaemia
- Phase I Renal failure
Most Recent Events
- 03 Dec 2024 Atom Therapeutics and China Medical System Holdings enter into an exclusive commercialization agreement for Lingdolinurad in China, Hongkong and Macau
- 14 Nov 2024 Phase-I clinical trials in Renal failure (PO) Prior to November 2024
- 14 Nov 2024 Pharmacokinetics data from a phase I trial in Renal failure presented at the American College of Rheumatology 2024 (ACR Convergence 2024)